FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression
1. FDA approved JNJ's Darzalex Faspro for high-risk multiple myeloma treatment. 2. Darzalex Faspro reduces disease progression risk by 51% versus active monitoring. 3. 63.1% of Darzalex Faspro patients remained disease-free at five years. 4. Caplyta also approved as adjunctive therapy for major depressive disorder. 5. Overall stock down 0.11% at $186.76 at publication.